Upstream Bio Inc
Follow $UPB
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $UPB by emailVeridion Score
BETALOW CONF · 4 of 6 factors measuredHighest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is UPB moving today?
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases. Verekitug has advanced into three separate world-wide, placebo-controlled, randomized Phase 2 clinical trials, two completed in chronic rhinosinusitis with nasal polyps (CRSwNP) and severe asthma, and one ongoing in chronic obstructive pulmonary disease (COPD).
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
UPB overview
Related filings and maps
Congress activity in UPB
No receipt-qualified Congressional disclosure is present for UPB in the cached public ledger.
UPB contract awards, year to date.
Public federal awards linked to this ticker.
UPB lobbying filings, year to date.
Registered lobbying filings matched to Upstream Bio Inc.